Design and synthesis of pyrimidine-5-carbonitrile hybrids as COX-2 inhibitors: Anti-inflammatory activity, ulcerogenic liability, histopathological and docking studies
作者:Abdallah M. Alfayomy、Salah A. Abdel-Aziz、Adel A. Marzouk、Montaser Sh. A. Shaykoon、Atsushi Narumi、Hiroyuki Konno、Sahar M. Abou-Seri、Fatma A.F. Ragab
DOI:10.1016/j.bioorg.2020.104555
日期:2021.3
Two new series of 1,3,4-oxadiazole and coumarin derivatives based on pyrimidine-5-carbonitrile scaffold have been synthesized and evaluated for their COX-1/COX-2 inhibitory activity. Compounds 10c, 10e, 10h-j, 14e-f, 14i and 16 were found to be the most potent and selective inhibitors of COX-2 (IC50 0.041-0.081 μM, SI 139.74-321.95). Eight compounds were further investigated for their in vivo anti-inflammatory
合成了两个新系列的基于 pyrimidine-5-carbonitrile 支架的 1,3,4-恶二唑和香豆素衍生物,并评估了它们的 COX-1/COX-2 抑制活性。发现化合物10c、10e、10h-j、14e-f、14i和16是最有效和选择性的 COX-2 抑制剂(IC 50 0.041-0.081 μM,SI 139.74-321.95)。进一步研究了八种化合物的体内抗炎活性。最活跃的衍生物10c , 10j和14e显示出优于参考药物塞来昔布的体内抗炎活性(水肿抑制百分比 39.3-48.3,1 小时;58.4-60.5,2 小时;70.8-83.2,3 小时;78.9-89.5,4 小时)(水肿抑制百分比 38.0) ,1 小时;48.8、2 小时;58.4、3 小时;65.4、4 小时)。还测试了这些衍生物的致溃疡倾向,化合物10j与塞来昔布相比表现出更好的安全性,而10c和14e表现出轻度损伤。COX-2